Cargando…
SMARCD3 is a potential prognostic marker and therapeutic target in CAFs
Objective: Screening for novel prognostic biomarkers and potential therapeutic targets from colorectal cancer microenvironment. Results: 372 genes were overexpressed in colorectal cancer microenvironment, five of which that had the most prognostic powers were enriched in Epithelial-Mesenchymal Trans...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655158/ https://www.ncbi.nlm.nih.gov/pubmed/33125346 http://dx.doi.org/10.18632/aging.104102 |
_version_ | 1783608182940106752 |
---|---|
author | Jiang, Ming Wang, Huiju Chen, Hong Han, Yong |
author_facet | Jiang, Ming Wang, Huiju Chen, Hong Han, Yong |
author_sort | Jiang, Ming |
collection | PubMed |
description | Objective: Screening for novel prognostic biomarkers and potential therapeutic targets from colorectal cancer microenvironment. Results: 372 genes were overexpressed in colorectal cancer microenvironment, five of which that had the most prognostic powers were enriched in Epithelial-Mesenchymal Transition and cell cycle pathways. For the first time, we showed that SMARCD3 was mainly expressed in CAFs and could be a novel prognostic marker and potential therapeutic target. Function analyses indicated that MSARCD3 might promote CAFs activation and colorectal cancer metastasis through SMARCD3-WNT5A/TGF-β-MAPK14-SMARCD3 positive feedback loop. Signaling map of SMARCD3 was constructed and several potential drugs that could regulate SMARCD3 were also presented. Conclusions: SMARCD3 is a novel prognostic biomarker and potential therapeutic target of colorectal cancer, which may promote cancer metastasis through activation of CAFs. Methods: Colorectal cancer microenvironment related genes were screened based on immune and stromal scores. Function enrichment analyses were performed to show the underlying mechanistic insights of these tumor microenvironment related genes. Kaplan-Meier survival analysis was used for evaluating the prognostic power. Gene-Pathway interaction network analysis and cellular heterogeneity analysis of tumor microenvironment were also performed. Gene set enrichment analysis was performed for signal gene pathway analysis. Protein data from The Cancer Genome Atlas were used for validation. |
format | Online Article Text |
id | pubmed-7655158 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Impact Journals |
record_format | MEDLINE/PubMed |
spelling | pubmed-76551582020-11-19 SMARCD3 is a potential prognostic marker and therapeutic target in CAFs Jiang, Ming Wang, Huiju Chen, Hong Han, Yong Aging (Albany NY) Research Paper Objective: Screening for novel prognostic biomarkers and potential therapeutic targets from colorectal cancer microenvironment. Results: 372 genes were overexpressed in colorectal cancer microenvironment, five of which that had the most prognostic powers were enriched in Epithelial-Mesenchymal Transition and cell cycle pathways. For the first time, we showed that SMARCD3 was mainly expressed in CAFs and could be a novel prognostic marker and potential therapeutic target. Function analyses indicated that MSARCD3 might promote CAFs activation and colorectal cancer metastasis through SMARCD3-WNT5A/TGF-β-MAPK14-SMARCD3 positive feedback loop. Signaling map of SMARCD3 was constructed and several potential drugs that could regulate SMARCD3 were also presented. Conclusions: SMARCD3 is a novel prognostic biomarker and potential therapeutic target of colorectal cancer, which may promote cancer metastasis through activation of CAFs. Methods: Colorectal cancer microenvironment related genes were screened based on immune and stromal scores. Function enrichment analyses were performed to show the underlying mechanistic insights of these tumor microenvironment related genes. Kaplan-Meier survival analysis was used for evaluating the prognostic power. Gene-Pathway interaction network analysis and cellular heterogeneity analysis of tumor microenvironment were also performed. Gene set enrichment analysis was performed for signal gene pathway analysis. Protein data from The Cancer Genome Atlas were used for validation. Impact Journals 2020-10-28 /pmc/articles/PMC7655158/ /pubmed/33125346 http://dx.doi.org/10.18632/aging.104102 Text en Copyright: © 2020 Jiang et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Jiang, Ming Wang, Huiju Chen, Hong Han, Yong SMARCD3 is a potential prognostic marker and therapeutic target in CAFs |
title | SMARCD3 is a potential prognostic marker and therapeutic target in CAFs |
title_full | SMARCD3 is a potential prognostic marker and therapeutic target in CAFs |
title_fullStr | SMARCD3 is a potential prognostic marker and therapeutic target in CAFs |
title_full_unstemmed | SMARCD3 is a potential prognostic marker and therapeutic target in CAFs |
title_short | SMARCD3 is a potential prognostic marker and therapeutic target in CAFs |
title_sort | smarcd3 is a potential prognostic marker and therapeutic target in cafs |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655158/ https://www.ncbi.nlm.nih.gov/pubmed/33125346 http://dx.doi.org/10.18632/aging.104102 |
work_keys_str_mv | AT jiangming smarcd3isapotentialprognosticmarkerandtherapeutictargetincafs AT wanghuiju smarcd3isapotentialprognosticmarkerandtherapeutictargetincafs AT chenhong smarcd3isapotentialprognosticmarkerandtherapeutictargetincafs AT hanyong smarcd3isapotentialprognosticmarkerandtherapeutictargetincafs |